The fact that even a genetic alteration as prevalent as FGFR3 mutation is by itself incapable of causing urothelial carcinoma in vivo, as we demonstrated here, illustrates the need to validate the molecular profiling data from human tumors using experimental systems. This evidence concerns the gene FGFR3 and urothelial carcinoma.